Differences in response to immunotherapy between KRAS G12C and KRAS non-G12C mutated NSCLC

被引：0
|
作者：
Pinto, L. Masfarre [1 ]
Rocha, P. [2 ]
Clave, S. [3 ]
Gorro, N. Navarro [4 ]
Sanchez, I. [3 ]
Giner, M. [5 ]
Lloret, A. Corbera [4 ]
Garcia, A. Taus [4 ]
Parreira, A. S. D. F. M. [6 ]
Paricio, B. Bellosillo [7 ]
Arriola, E. [1 ]
机构：
[1] Hosp Mar Parc Salut Mar, Dept Oncol, Barcelona, Spain
[2] Hosp Mar Parc Salut Mar, Translat Mol Pathol Dept, Barcelona, Spain
[3] Hosp Mar Parc Salut Mar, Dept Pathol, Barcelona, Spain
[4] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain
[5] Hosp Mar Parc Salut Mar, Barcelona, Spain
[6] Hosp Univ Son Espases, Med Oncol, Palma De Mallorca, Spain
[7] Hosp Mar Parc Salut Mar, Dept Mol Biol, Barcelona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
193P
引用
收藏
页码：S145 / S146
页数：2
相关论文
共 50 条
  • [21] Mechanisms of Resistance to KRAS G12C Inhibitors
    Ambrogio, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S96 - S96
  • [22] Impact of Sotorasib and Adagrasib in KRAS G12C-Mutated NSCLC
    Patel, Sandip P.
    ONCOLOGY-NEW YORK, 2023, 37 (12): : 479 - 479
  • [23] Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
    Noordhof, Anneloes L.
    Swart, Esther M.
    Damhuis, Ronald A. M.
    Hendriks, Lizza E. L.
    Kunst, Peter W. A.
    Aarts, Mieke J.
    van Geffen, Wouter H.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (09):
  • [24] 31507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).
    Gadgeel, Shirish M.
    Miao, Jieling
    Riess, Jonathan W.
    Mack, Philip C.
    Gerstner, Gregory James
    Burns, Timothy F.
    Taj, Asma
    Akerley, Wallace L.
    Dragnev, Konstantin H.
    Moon, James
    Gandara, David R.
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Establishment of KRAS G12C mutant brain metastasis models for preclinical evaluation of KRAS G12C targeted anticancer therapy
    Chen, Qikuan
    Wang, Guilan
    Yin, Yingfei
    CANCER RESEARCH, 2024, 84 (06)
  • [26] Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
    Choi, Yoonha
    Dharia, Neekesh V.
    Jun, Tomi
    Chang, Julie
    Royer-Joo, Stephanie
    Yau, Kenneth K.
    Assaf, Zoe J.
    Aimi, Junko
    Sivakumar, Smruthy
    Montesion, Meagan
    Sacher, Adrian
    LoRusso, Patricia
    Desai, Jayesh
    Schutzman, Jennifer L.
    Shi, Zhen
    CLINICAL CANCER RESEARCH, 2024, 30 (17) : 3788 - 3797
  • [27] Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
    Fakih, Marwan G.
    Salvatore, Lisa
    Esaki, Taito
    Modest, Dominik P.
    Lopez-Bravo, David P.
    Taieb, Julien
    Karamouzis, Michalis V.
    Ruiz-Garcia, Erika
    Kim, Tae-Won
    Kuboki, Yasutoshi
    Meriggi, Fausto
    Cunningham, David
    Yeh, Kun-Huei
    Chan, Emily
    Chao, Joseph
    Saportas, Yaneth
    Tran, Qui
    Cremolini, Chiara
    Pietrantonio, Filippo
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (23): : 2125 - 2139
  • [28] Targeting the KRAS G12C Mutation in NSCLC For a early, deep and sustained Remission
    Fessler, Beate
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (04) : 230 - 230
  • [29] KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
    Lim, Tony Kiat Hon
    Skoulidis, Ferdinandos
    Kerr, Keith M.
    Ahn, Myung-Ju
    Kapp, Joshua R.
    Soares, Fernando A.
    Yatabe, Yasushi
    LUNG CANCER, 2023, 184
  • [30] Development of inhibitors of the activated form of KRAS G12C
    Pollock, R.
    Stewart, M.
    Perl, N.
    Lee, S. J.
    Xue, L.
    Zhou, M.
    Simon, J.
    Luly, K.
    Grigoriu, S.
    Yuzhakov, A.
    Silver, A.
    Lowe, J.
    Mann, A.
    Verdine, G.
    Rigby, A.
    Mulvihill, M.
    May, E.
    Kohlmann, A.
    Townson, S.
    Jin, M.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E52 - E52
12345